Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

RJ Eckersley; JPM Sedelaar; MJK Blomley; H Wijkstra; NM deSouza; DO Cosgrove; JJMCH de la Rosette

doi:10.1002/pros.10065

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

RJ Eckersley^*, JPM Sedelaar, MJK Blomley, H Wijkstra, NM deSouza, DO Cosgrove, JJMCH de la Rosette

^*Corresponding author for this work

Biomedical Engineering Department

Research output: Contribution to journal › Article › peer-review

75 Citations (Scopus)

Abstract

Background. We quantified changes in Prostate carcinoma vascularity treated with anti-androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist(R).

Methods. Thirty-six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist(R) (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre-enhancement scores, arrival time, time to peak, peak value, and area under the time-enhancement curve (AUC). These were compared to pre-treatment values and serial PSA measurements.

Results. The pre-enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68%+/-9% (mean+/-standard error) by week 1, 56%+/-9% by week 3, and 20%+/-4% by week 6. A strong correlation with changes in the mean PSA (r=0.95, P

Conclusion. The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment.

Original language	English
Pages (from-to)	256-267
Number of pages	12
Journal	Prostate
Volume	51
Issue number	4
DOIs	https://doi.org/10.1002/pros.10065
Publication status	Published - 1 Jun 2002

Keywords

contrast enhanced ultrasound imaging
prostate cancer
hormonal treatment
treatment follow-up
COLOR DOPPLER US
CONTRAST AGENT
MICROVESSEL DENSITY
PATHOLOGICAL STAGE
CANCER
SONOGRAPHY
TUMOR
ULTRASONOGRAPHY
QUANTIFICATION
PERSPECTIVES

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/pros.10065

Cite this

@article{67cb42bc57ca409faa4acbebb620f058,

title = "Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma",

abstract = "Background. We quantified changes in Prostate carcinoma vascularity treated with anti-androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist(R).Methods. Thirty-six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist(R) (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre-enhancement scores, arrival time, time to peak, peak value, and area under the time-enhancement curve (AUC). These were compared to pre-treatment values and serial PSA measurements.Results. The pre-enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68%+/-9% (mean+/-standard error) by week 1, 56%+/-9% by week 3, and 20%+/-4% by week 6. A strong correlation with changes in the mean PSA (r=0.95, PConclusion. The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment.",

keywords = "contrast enhanced ultrasound imaging, prostate cancer, hormonal treatment, treatment follow-up, COLOR DOPPLER US, CONTRAST AGENT, MICROVESSEL DENSITY, PATHOLOGICAL STAGE, CANCER, SONOGRAPHY, TUMOR, ULTRASONOGRAPHY, QUANTIFICATION, PERSPECTIVES",

author = "RJ Eckersley and JPM Sedelaar and MJK Blomley and H Wijkstra and NM deSouza and DO Cosgrove and {de la Rosette}, JJMCH",

year = "2002",

month = jun,

day = "1",

doi = "10.1002/pros.10065",

language = "English",

volume = "51",

pages = "256--267",

journal = "Prostate",

issn = "0270-4137",

publisher = "Wiley",

number = "4",

}

TY - JOUR

T1 - Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

AU - Eckersley, RJ

AU - Sedelaar, JPM

AU - Blomley, MJK

AU - Wijkstra, H

AU - deSouza, NM

AU - Cosgrove, DO

AU - de la Rosette, JJMCH

PY - 2002/6/1

Y1 - 2002/6/1

N2 - Background. We quantified changes in Prostate carcinoma vascularity treated with anti-androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist(R).Methods. Thirty-six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist(R) (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre-enhancement scores, arrival time, time to peak, peak value, and area under the time-enhancement curve (AUC). These were compared to pre-treatment values and serial PSA measurements.Results. The pre-enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68%+/-9% (mean+/-standard error) by week 1, 56%+/-9% by week 3, and 20%+/-4% by week 6. A strong correlation with changes in the mean PSA (r=0.95, PConclusion. The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment.

AB - Background. We quantified changes in Prostate carcinoma vascularity treated with anti-androgens using color Doppler and power transrectal ultrasound in combination with microbubble contrast agent Levovist(R).Methods. Thirty-six men with prostate carcinoma were studied at baseline and at intervals during treatment. At each attendance, Levovist(R) (10 ml, 300 mg/ml) was given as an iv bolus. Using quantitative analysis, we calculated the pre-enhancement scores, arrival time, time to peak, peak value, and area under the time-enhancement curve (AUC). These were compared to pre-treatment values and serial PSA measurements.Results. The pre-enhancement, peak value, and AUC each showed a marked response with reductions within one week. The average AUC declined to 68%+/-9% (mean+/-standard error) by week 1, 56%+/-9% by week 3, and 20%+/-4% by week 6. A strong correlation with changes in the mean PSA (r=0.95, PConclusion. The vascular enhancement declined with therapy, similar to PSA. Microbubble enhanced ultrasound can show early response to treatment.

KW - contrast enhanced ultrasound imaging

KW - prostate cancer

KW - hormonal treatment

KW - treatment follow-up

KW - COLOR DOPPLER US

KW - CONTRAST AGENT

KW - MICROVESSEL DENSITY

KW - PATHOLOGICAL STAGE

KW - CANCER

KW - SONOGRAPHY

KW - TUMOR

KW - ULTRASONOGRAPHY

KW - QUANTIFICATION

KW - PERSPECTIVES

U2 - 10.1002/pros.10065

DO - 10.1002/pros.10065

M3 - Article

SN - 0270-4137

VL - 51

SP - 256

EP - 267

JO - Prostate

JF - Prostate

IS - 4

ER -

Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this